New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > GYN OV Advanced - olaparib

GYN OV Advanced - olaparib

Treatment Overview

This regimen is for treatment with olaparib tablets only.

Cycle 1 (and all further cycles) - 28 days

Cycle length:
28

This regimen is for treatment with olaparib tablets only.


Emetogenicity: MEDIUM to HIGH. Routine antiemetic premedication may not be required for continuous dosing of oral anti-cancer medicines with MEDIUM to HIGH emetic risk; an individualised approach is appropriate.

Cycle details

Cycle 1 (and all further cycles) - 28 days

Medication Dose Route Days Max Duration
olaparib 300 mg Twice daily oral administration 1 to 28
domperidone 10 mg Three times daily oral administration 1

This regimen is for treatment with olaparib tablets only.


Emetogenicity: MEDIUM to HIGH. Routine antiemetic premedication may not be required for continuous dosing of oral anti-cancer medicines with MEDIUM to HIGH emetic risk; an individualised approach is appropriate.

Full details

Cycle 1 (and all further cycles) - 28 days

Day: 1

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).
domperidone 10 mg Three times daily oral administration
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.

Day: 2

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 3

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 4

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 5

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 6

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 7

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 8

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 9

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 10

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 11

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 12

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 13

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 14

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 15

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 16

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 17

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 18

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 19

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 20

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 21

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 22

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 23

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 24

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 25

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 26

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 27

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Day: 28

Medication Dose Route Max duration Details
olaparib 300 mg Twice daily oral administration
Instructions:
Swallow whole, do not crush or chew. Avoid food containing grapefruit or Seville oranges during treatment. May affect performance of skilled tasks (e.g. driving).

Supportive Care Factors

Factor Value
Emetogenicity: Medium to high

References

Pujade-Lauraine, E., J. A. Ledermann, F. Selle, et al. 2017. "Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial." Lancet Oncol 18(9):1274-1284., PMID: 28754483

Moore, K., N. Colombo, G. Scambia, et al. 2018. "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer." N Engl J Med 379(26):2495-2505., PMID: 30345884

Friedlander, M., K. N. Moore, N. Colombo, et al. 2021. "Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial." Lancet Oncol 22(5):632-642., PMID: 33862001

Friedlander, M., V. Gebski, E. Gibbs, et al. 2018. "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial." Lancet Oncol 19(8):1126-1134., PMID: 30026002

Poveda, A., A. Floquet, J. A. Ledermann, et al. 2021. "Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial." Lancet Oncol 22(5):620-631., PMID: 33743851

AstraZeneca Limited. Lynparza Tablets New Zealand Data Sheet 05 February 2021. https://www.medsafe.govt.nz/profs/Datasheet/l/lynparzatab.pdf (Accessed 08 June 2021)

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.